Mirum registers Phase 2 trial of maralixibat for cholestasis of pregnancy

Mirum Pharmaceuticals had one registry update this week, a newly listed early-stage study in a pregnancy-related liver condition.

• "MRX-901," known by the acronym OASIS, is a Phase 2 open-label study of maralixibat in participants with intrahepatic cholestasis of pregnancy, sponsored by Mirum Pharmaceuticals and listed as not yet recruiting with an estimated start of January 15, 2027. The study plans to enroll 15 participants¹ and will assess incidence of treatment-emergent adverse events from first dose until approximately 42 days after delivery¹.